India Pharma Outlook Team | Wednesday, 17 June 2026
Kiran Mazumdar-Shaw is placing one of Biocon's biggest bets on a market many pharmaceutical companies are no longer prioritizing.
As global drugmakers rush to capitalize on the booming demand for GLP-1 and obesity drugs, the Biocon founder believes insulin still offers significant growth potential. With Kiran Mazumdar-Shaw now aiming to make Biocon the world's largest insulin supplier, the move highlights a changing dynamic in the global diabetes treatment market.
The ambition comes at a time when several leading pharmaceutical companies are investing heavily in newer therapies that promise higher growth and better margins. Yet insulin remains an essential medicine for millions of people living with diabetes, creating an opportunity that Biocon believes is far from exhausted.
The global conversation around diabetes treatment has shifted in recent years. Drugs such as GLP-1 therapies have gained attention because of their role in both diabetes management and weight loss. This has prompted many companies to channel resources toward these fast-growing segments.
However, insulin continues to play a critical role in diabetes care.
For patients with Type 1 diabetes and many people with advanced Type 2 diabetes, insulin remains a necessity rather than an option. Rising diabetes rates across the world are also expected to support long-term demand for insulin products.
Biocon sees several factors working in its favor:
This shift in industry priorities could allow Biocon to strengthen its position in a market that remains vital to healthcare systems worldwide.
Also Read: AI-Augmented Clinical Trials & Drug Development Evolution in India
For those who have followed Biocon's journey, the insulin strategy may sound familiar.
Throughout her career, Kiran Mazumdar-Shaw has often entered sectors before they became mainstream opportunities. Biocon invested early in biotechnology and biosimilars at a time when much of the Indian pharmaceutical industry was focused on conventional generics.
That long-term approach helped transform the company into one of India's leading biotechnology firms.
The latest insulin push follows a similar pattern. Rather than chasing the same opportunities as larger rivals, Biocon is targeting a segment where it believes demand will remain strong even as industry attention shifts elsewhere.
The company already has a significant presence in diabetes care and biosimilars, providing a foundation for future growth in insulin markets.
Becoming the world's largest insulin supplier will not be easy.
The global insulin market has long been dominated by major multinational pharmaceutical companies with established manufacturing networks, distribution channels, and brand recognition. Scaling production, expanding market access, and meeting regulatory requirements across multiple regions will remain key challenges.
At the same time, Biocon enters the race with important advantages:
If the company can successfully scale its insulin business, it could emerge as one of the most influential players in global diabetes care.
More importantly, the strategy reflects a broader shift within India's pharmaceutical industry. Companies are increasingly moving beyond traditional generics and targeting complex biologics, specialty medicines, and advanced therapies.
As many global drugmakers focus on the next generation of obesity treatments, Kiran Mazumdar-Shaw is betting that one of healthcare's oldest and most essential medicines still has room for growth. Whether Biocon achieves its ambitious target remains to be seen, but the company is clearly positioning itself to capitalize on an opportunity others may be overlooking.
Biocon is a Bengaluru-based biotechnology company founded in 1978 by Kiran Mazumdar-Shaw. The company operates across biosimilars, generics, novel biologics, and research services and has a presence in more than 120 countries.
.jpg)
